R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Patients Pharmacy benefits: Lessons from 2024 and what lies ahead for... The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts.
Market Access Why the NHS needs to maximise the impact of biosimilars Ensuring the long-term sustainability of the NHS increasingly appears to be an unfathomable prospect.
News Legal win leads Amgen to at-risk launch of Eylea biosimilar Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal
Market Access Inflation Reduction Act proves positive boost for biosimilar... For the pharma industry, the IRA has made headlines due to it allowing price negotiations on top-selling treatments.
News Blue Shield of California bypasses PBMs to slash Humira pric... Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the price of Humira by up to 90%
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
